Javascript is disabled or is not supported by your browser. Please upgrade your browser or enable Javascript to navigate the interface properly.

Vivo Capital

Latest statistics and disclosures from Vivo Capital's latest quarterly 13F-HR filing:

Top 5 stock holdings are SLNO, VRNA, GERN, TERN, AVDL, and represent 61.80% of Vivo Capital's stock portfolio.
Added to shares of these 8 stocks: ACRS (+$22M), CDTX (+$18M), DRUG (+$9.1M), DCTH (+$8.6M), TRVI (+$7.7M), UNCY, CRVS, Dbv Technologies Sa.
Started 4 new stock positions in DRUG, CDTX, ACRS, Dbv Technologies Sa.
Reduced shares in these 10 stocks: HRMY (-$104M), , VRNA (-$59M), VRDN (-$13M), ALXO (-$7.3M), ADVM (-$5.8M), ENGN, CDXS, DBVT, TIL.
Sold out of its positions in ALXO, ADVM, CDXS, DBVT, ENGN, HRMY, Sinovac Biotech.
Vivo Capital was a net seller of stock by $-199M.
Vivo Capital has $893M in assets under management (AUM), dropping by -26.13%.
Central Index Key (CIK): 0001674712

Tip: Access up to 7 years of quarterly data

Positions held by Vivo Capital consolidated in one spreadsheet with up to 7 years of data

Download as csv

Download as Excel

Portfolio Holdings for Vivo Capital

Vivo Capital holds 40 positions in its portfolio as reported in the December 2024 quarterly 13F filing

Company (Ticker)	Portfolio Weight	Valued At	Change in Shares	Share Count	Share Price
Soleno Therapeutics Common (SLNO)	31.7	$283M		6.3M	44.95	View chart
Verona Pharma Sponsored Ads (VRNA)	11.9	$106M	-35%	2.3M	46.44	View chart
Geron Corp Common (GERN)	10.8	$96M		27M	3.54	View chart
Terns Pharmaceuticals Common (TERN)	4.3	$38M		6.9M	5.54	View chart
Avadel Pharmaceuticals Adr (AVDL)	3.2	$28M		2.7M	10.51	View chart
Dyne Therapeutics Common (DYN)	2.9	$26M		1.1M	23.56	View chart
Aclaris Therapeutics Common (ACRS)	2.5	$22M	NEW	8.9M	2.48	View chart
Delcath Systems Common (DCTH)	2.3	$21M	+71%	1.7M	12.04	View chart
Viridian Therapeutics Common (VRDN)	2.1	$19M	-41%	983k	19.17	View chart
Cidara Therapeutics Common (CDTX)	2.0	$18M	NEW	671k	26.88	View chart
Erasca Common (ERAS)	1.9	$17M		6.8M	2.51	View chart
Trevi Therapeutics Common (TRVI)	1.6	$14M	+116%	3.5M	4.12	View chart
Astria Therapeutics Common (ATXS)	1.6	$14M		1.6M	8.94	View chart
Rezolute Common (RZLT)	1.5	$14M		2.8M	4.90	View chart
Sera Prognostics Common (SERA)	1.5	$13M		1.7M	8.14	View chart
Tourmaline Bio Common (TRML)	1.3	$12M		592k	20.28	View chart
Corvus Pharmaceuticals Holdings Common (CRVS)	1.3	$12M	+49%	2.2M	5.35	View chart
Instil Bio Common (TIL)	1.3	$11M	-6%	586k	19.09	View chart
Oric Pharmaceuticals Common (ORIC)	1.2	$10M		1.3M	8.07	View chart
Abeona Therapeutics Common (ABEO)	1.1	$10M		1.8M	5.57	View chart
Zenas Biopharma Common (ZBIO)	1.1	$9.7M		1.2M	8.19	View chart
Bright Minds Biosciences Common (DRUG)	1.0	$9.1M	NEW	252k	36.02	View chart
Olema Pharmaceuticals Common (OLMA)	1.0	$8.8M		1.5M	5.83	View chart
Cogent Biosciences Common (COGT)	1.0	$8.8M		1.1M	7.80	View chart
Celcuity Common (CELC)	0.9	$8.0M		611k	13.09	View chart
Verastem Common (VSTM)	0.9	$8.0M		1.5M	5.17	View chart
Unicycive Therapeutics Common (UNCY)	0.9	$7.9M	+123%	10M	0.79	View chart
Regulus Therapeutics Common (RGLS)	0.9	$7.9M		5.0M	1.58	View chart
Silence Therapeutics Ads (SLN)	0.9	$7.6M		1.1M	6.88	View chart
Compass Pathway Sponsored Ads (CMPS)	0.7	$6.1M		1.6M	3.78	View chart
IO Biotech Common (IOBT)	0.6	$5.7M		6.2M	0.92	View chart
Aligos Therapeutics Common (ALGS)	0.6	$5.7M		142k	39.84	View chart
Compass Therapeutics Common (CMPX)	0.6	$5.2M		3.6M	1.45	View chart
Allakos Common (ALLK)	0.4	$3.6M		3.0M	1.21	View chart
Corbus Pharmaceuticals Holdings Common (CRBP)	0.2	$2.0M		167k	11.80	View chart
Bolt Therapeutics Common (BOLT)	0.2	$1.9M		3.5M	0.54	View chart
Tenax Therapeutics Common (TENX)	0.1	$1.3M		208k	6.19	View chart
DBV Technologies SA Sponsored Ads	0.0	$99k	NEW	32k	3.09	View chart
Q32 Bio Common (QTTB)	0.0	$71k		21k	3.44	View chart
Precision Biosciences Common (DTIL)	0.0	$18k		4.7k	3.81	View chart

Past Filings by Vivo Capital

SEC 13F filings are viewable for Vivo Capital going back to 2016

Vivo Capital 2024 Q4 filed Feb. 13, 2025
Vivo Capital 2024 Q3 filed Nov. 13, 2024
Vivo Capital 2024 Q2 filed Aug. 14, 2024
Vivo Capital 2024 Q1 filed April 22, 2024
Vivo Capital 2023 Q4 filed Feb. 7, 2024
Vivo Capital 2023 Q3 filed Nov. 8, 2023
Vivo Capital 2023 Q2 filed Aug. 14, 2023
Vivo Capital 2023 Q1 filed May 15, 2023
Vivo Capital 2022 Q4 filed Feb. 13, 2023
Vivo Capital 2022 Q3 filed Nov. 14, 2022
Vivo Capital 2022 Q2 filed Aug. 15, 2022
Vivo Capital 2022 Q1 filed May 13, 2022
Vivo Capital 2021 Q4 filed Feb. 11, 2022
Vivo Capital 2021 Q3 filed Nov. 15, 2021
Vivo Capital 2021 Q2 filed Aug. 16, 2021
Vivo Capital 2021 Q1 filed May 17, 2021

View all past filings

Disclaimers: stockzoa.com is not operated by a broker, a dealer, or a registered investment adviser. Under no circumstances does any information posted on stockzoa.com represent a recommendation to purchase or sell a stock. The information on this site is not intended to be, nor does it constitute, investment advice or recommendations. The information on this site is in no way guaranteed for completeness, accuracy or in any other way. In no event shall stockzoa.com be liable to any member, guest or third party for any damages of any kind arising out of the use of any content available on stockzoa.com, or relating to the use of, or inability to use, stockzoa.com or any content, including, without limitation, any investment losses, lost profits, lost opportunity, special, incidental, indirect, consequential or punitive damages. Past performance is a poor indicator of future performance.

Fund Directory: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X-Z